For patients with metabolic dysfunction-associated steatohepatitis (MASH) and fibrosis, semaglutide is associated with improved liver histologic outcomes.

With more and more people signing up for weight loss drugs, the potential side effects are starting to attract attention.

Over time, scar tissue slows or stops implanted bioelectronics. But new interdisciplinary research could help pacemakers, ...

The FDA will decide whether to approve a once-daily, 25 mg oral formulation of semaglutide (Wegovy) by the end of 2025. If ...